TransCode Therapeutics announces it has submitted an IND amendment to the FDA for a planned Phase 2a PRE-I-SPY clinical trial of its lead candidate TTX-MC138 in colorectal cancer.
https://finviz.com/quote.ashx?t=RNAZ&p=d
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.